Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Diadié Maïga"'
Autor:
Deborah F. King, Helen Groves, Charlie Weller, Ian Jones, Jakob P. Cramer, Peter B. Gilbert, David Goldblatt, Marion F. Gruber, Beate Kampmann, Diadié Maïga, Marcela F. Pasetti, Stanley A. Plotkin, Alexander Precioso, Liya Wassie, Frederick Wittke, David C. Kaslow
Publikováno v:
npj Vaccines, Vol 9, Iss 1, Pp 1-9 (2024)
On 27–29th of September 2022, Wellcome convened an international multi-stakeholder workshop to discuss the use of Correlates of Protection (CoP) to accelerate vaccine development, the hybrid format meeting was attended by 80 delegates including dev
Externí odkaz:
https://doaj.org/article/b667f597503a47e59f0908a1ed984fa8
Autor:
Claudia P. Alfonso, Guy B. N’Jambong, Alaa Magdy, Laura Di Trapani, Rutendo Kuwana, Abraham G. Kahsay, Diadié Maïga, Sybil N. A. Ossei-Agyeman-Yeboah, Aimé B. Djitafo Fah, Margareth Ndomondo-Sigonda
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundRegulatory systems strengthening is crucial for catalyzing access to safe and effective medical products and health technologies (MPHT) for all. Identifying and addressing common regulatory gaps through regional approaches could be instrume
Externí odkaz:
https://doaj.org/article/5bd9902bb9dc4a56a2ee0219714c2bdc
Autor:
Courtney L. Finch, Christian Martinez, Elizabeth Leffel, Mario H. Skiadopoulos, Adam Hacker, Betty Mwesigwa, Diadié Maïga, Ian Mugisa, Grant Munkwase, Roxana Rustomjee
Publikováno v:
Vaccines, Vol 10, Iss 3, p 368 (2022)
Clinical vaccine development and regulatory approval generally occurs in a linear, sequential manner: Phase 1: safety, immunogenicity; Phase 2: immunogenicity, safety, dose ranging, and preliminary efficacy; Phase 3: definitive efficacy, safety, lot
Externí odkaz:
https://doaj.org/article/df1fced8fd35458ab96d4e513036593b
Publikováno v:
Revue Gouvernance, Vol 8, Iss 1 (2011)
Depuis 2005, le Mali participe à des activités de renforcement des autorités nationales de réglementation (ANR) initiées par l’OMS en vue d’une bonne régulation des essais cliniques. Malgré cette participation, il y a peu de régulation de
Externí odkaz:
https://doaj.org/article/30b3bb8994f44e78a733141a0c6068d3
Autor:
Vasee S. Moorthy, Adebola Olayinka, Pete Smith, Diadié Maïga, Pierre Formenty, Kolawole Salami, Pierre-Stéphane Gsell
Publikováno v:
Vaccine. 38:4135-4141
At the time of writing in 2019, there have been 754 confirmed cases of Lassa fever in Nigeria, 21% of whom have died. Lassa is on the priority pathogen list for WHO’s R&D Blueprint for Action to Prevent Epidemics. In September 2019, WHO convened 67
Publikováno v:
Vaccine. 28:571-575
Vaccine developers are required to submit a clinical trial application to the authorities in each country where a clinical trial will be conducted. The application has to be made both to the relevant Ethics Committees and to the National Regulatory A
Autor:
Bryn Williams-Jones, Diadié Maïga
Publikováno v:
Health policy (Amsterdam, Netherlands). 97(2-3)
Objective In 1998, the government of Mali adopted a national pharmaceutical policy aimed at promoting a supply system for generic essential medicines that would guarantee equal access for all citizens. Distribution and delivery is a shared responsibi
Publikováno v:
Vaccine. 27(52)
Randomized controlled clinical trials represent the best way to establish the therapeutic or preventive value of medicines. This decade has seen a strong shift in the location of clinical trials from industrialized countries to developing countries,
Publikováno v:
Health Research Policy and Systems, Vol 5, Iss 1, p 2 (2007)
Health research policy and systems / BioMed Central
Health Research Policy and Systems
Health research policy and systems / BioMed Central
Health Research Policy and Systems
Background Research findings are increasingly being recognized as an important input in the formation of health policy. There is concern that research findings are not being utilized by health policy-makers to the extent that they could be. The facto
Depuis 2005, le Mali participe à des activités de renforcement des autorités nationales de réglementation (ANR) initiées par l’OMS en vue d’une bonne régulation des essais cliniques. Malgré cette participation, il y a peu de régulation de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de49c2ab5b62b42d756d5a160522187
https://id.erudit.org/iderudit/1038917ar
https://id.erudit.org/iderudit/1038917ar